Patents Represented by Attorney, Agent or Law Firm Gregg C. Benson
  • Patent number: 8178574
    Abstract: The present invention is directed to the tosylate salt of trans-N-isobutyl-3-fluoro-3-[3-fluoro-4-(pyrrolidin-1-ylmethyl)-phenyl]-cyclobutanecarboxamide Formula (I): to solvates (e.g., hydrates) thereof, to polymorphs thereof, to pharmaceutical compositions thereof and to a method of treating depression, mood disorders, schizophrenia, anxiety disorders, cognitive disorders, Alzheimer's disease, attention-deficit disorder (ADD), attention-deficit hyperactivity disorder (ADHD), psychotic disorders, sleep disorders, obesity, dizziness, epilepsy, motion sickness, respiratory diseases, allergy, allergy-induced airway responses, allergic rhinitis, nasal congestion, allergic congestion, congestion, hypotension, cardiovascular disease, diseases of the GI tract, hyper- and hypo-motility and acidic secretion of the gastro-intestinal tract comprising administering a therapeutically effective amount thereof.
    Type: Grant
    Filed: December 4, 2008
    Date of Patent: May 15, 2012
    Assignee: Pfizer Inc.
    Inventors: Travis T. Wager, Todd W. Butler
  • Patent number: 8158673
    Abstract: This invention is directed to a compound of formula I, as defined herein, or a pharmaceutically acceptable salt thereof; a pharmaceutical composition containing a compound of formula I, a process of preparation of a compound of formula I, a method of treatment of a disorder or condition that may be treated by antagonizing histamine H3 receptors, the method comprising administering to a mammal in need of such treatment a compound of formula I as described above, and a method of treatment of a disorder or condition selected from the group consisting of depression, mood disorders, schizophrenia, anxiety disorders, Alzheimer's disease, attention-deficit hyperactivity disorder (ADHD), psychotic disorders, cognitive disorders, sleep disorders, obesity, dizziness, epilepsy, motion sickness, respiratory diseases, allergy, allergy-induced airway responses, allergic rhinitis, nasal congestion, allergic congestion, congestion, hypotension, cardiovascular disease, diseases of the GI tract, hyper and hypo motility and
    Type: Grant
    Filed: October 13, 2006
    Date of Patent: April 17, 2012
    Assignee: Pfizer Inc.
    Inventors: Travis T. Wager, Ramalakshmi Y Chandrasekaran, Todd William Butler
  • Patent number: 8138188
    Abstract: The present invention relates to a class of melanocortin MCR4 agonists of general formula (I) wherein the variables and substituents are as defined herein and especially to selective MCR4 agonist compounds, to their use in medicine, particularly in the treatment of sexual dysfunction and obesity, to intermediates useful in their synthesis and to compositions containing them.
    Type: Grant
    Filed: February 19, 2007
    Date of Patent: March 20, 2012
    Assignee: Pfizer Inc.
    Inventors: Mark David Andrews, Alan Daniel Brown, Mark Ian Lansdell, Nicholas William Summerhill
  • Patent number: 8124610
    Abstract: Compounds, compositions and methods are provided which are useful in the treatment of diseases through the inhibition of sodium ion flux through voltage-gated sodium channels. More particularly, the invention provides substituted sulfonamides, compositions comprising these compounds, as well as methods of using these compounds or compositions in the treatment of central or peripheral nervous system disorders, particularly pain and chronic pain by blocking sodium channels associated with the onset or recurrence of the indicated conditions. The compounds, compositions and methods of the present invention are of particular use for treating neuropathic or inflammatory pain by the inhibition of ion flux through a voltage-gated sodium channel.
    Type: Grant
    Filed: July 14, 2008
    Date of Patent: February 28, 2012
    Assignee: Icagen Inc.
    Inventors: Alan Bradley Fulp, Matthew Scott Johnson, Christopher John Markworth, Brian Edward Marron, Darrick Conway Seconi, Christopher William West, Xiaodong Wang, Shulan Zhou
  • Patent number: 8124639
    Abstract: The present invention relates to a series of substituted bicyclic[3.1.0]heteroaryl amides of the Formula I, wherein A, Q, X, Y, Z and R1-R5 groups are defined as in the specification, that exhibit activity as glycine transport inhibitors, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, and their use for the enhancement of cognition and the treatment of the positive and negative symptoms of schizophrenia and other psychoses in mammals, including humans.
    Type: Grant
    Filed: August 30, 2010
    Date of Patent: February 28, 2012
    Assignee: Pfizer Inc.
    Inventors: Stanton F. McHardy, John A. Lowe, III
  • Patent number: 8093400
    Abstract: The present invention provides compounds of formula (I), or pharmaceutically acceptable derivatives thereof wherein the variables Z, Q, Ring A, V, X, Y and Y? are as defined herein, and pharmaceutical compositions comprising these compounds. The compounds of formula (I) and pharmaceutical compositions comprising them are useful for treating a disorder for which a V1a antagonist is indicated, in particular, dysmenorrhoea.
    Type: Grant
    Filed: May 11, 2010
    Date of Patent: January 10, 2012
    Assignee: Pfizer Inc.
    Inventors: Justin Stephen Bryans, Patrick Stephen Johnson, Lee Richard Roberts, Thomas Ryckmans
  • Patent number: 7820825
    Abstract: The present invention provides a compound of formula I and the use thereof for the treatment of a central nervous system disorder related to or affected by the histamine-3 receptor.
    Type: Grant
    Filed: March 14, 2007
    Date of Patent: October 26, 2010
    Assignee: Wyeth LLC
    Inventors: Derek Cecil Cole, Magda Asselin, Joseph Raymond Stock, Albert Jean Robichaud, Ji-In Kim, William Ronald Solvibile, Jonathan Laird Gross
  • Patent number: 7807165
    Abstract: Monoclonal antibody 9TL and antibodies derived from 9TL directed against amyloid-beta peptide and methods of using same for diagnosing and treatment of Alzheimer's disease and A? peptide associated diseases are described. Methods of using antibodies directed against amyloid-beta peptide having impaired effector function for treatment of Alzheimer's disease and A? peptide associated diseases are also described.
    Type: Grant
    Filed: August 1, 2005
    Date of Patent: October 5, 2010
    Assignee: Rinat Neuroscience Corp.
    Inventors: Arnon Rosenthal, Jaume Pons, Wei-Hsien Ho, Jan Markus Grimm
  • Patent number: 7803825
    Abstract: The present invention provides a compound of formula Ia: and the use thereof for the treatment of a central nervous system disorder related to or affected by the histamine-3 receptor.
    Type: Grant
    Filed: July 15, 2008
    Date of Patent: September 28, 2010
    Assignee: Wyeth LLC
    Inventors: Jonathan Laird Gross, Albert Jean Robichaud, Marla Jean Williams, Alessandro Mazzacani
  • Patent number: 7772223
    Abstract: The invention relates to compounds of formula processes and intermediates for their preparation, their use as muscarinic antagonists and pharmaceutical composition containing them.
    Type: Grant
    Filed: September 18, 2006
    Date of Patent: August 10, 2010
    Assignee: Pfizer Inc.
    Inventors: Paul Alan Glossop, Simon John Mantell, Anthony Wood, Christine Anne Louise Watson
  • Patent number: 7772269
    Abstract: The invention relates to the compounds of formula (I): or a pharmaceutically acceptable salt and solvate thereof, wherein R1 is F or H and to processes for the preparation of, intermediates used in the preparation of, compositions containing the uses of, such compounds. The compounds according to the present invention are useful in numerous diseases, disorders and conditions, in particular allergic and respiratory diseases, disorders and conditions.
    Type: Grant
    Filed: November 26, 2007
    Date of Patent: August 10, 2010
    Assignee: Pfizer Inc.
    Inventors: Mathew J. Graneto, Todd M. Maddux, Jaime L. Masferrer
  • Patent number: 7771748
    Abstract: The present invention is directed to controlled-release (CR) oral pharmaceutical dosage forms of 5,8,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaene, 1, and pharmaceutically acceptable salts thereof, and methods of using them to reduce nicotine addiction or aiding in the cessation or lessening of tobacco use while reducing nausea as an adverse effect. The present invention also relates to an immediate-release (IR) low dosage composition having a stable formulation with uniform drug distribution and potency.
    Type: Grant
    Filed: November 20, 2002
    Date of Patent: August 10, 2010
    Assignee: Pfizer Inc
    Inventors: Mary T. Am Ende, Michael C. Roy, Scott W. Smith, Kenneth C. Waterman, Sara Kristen Moses
  • Patent number: 7767715
    Abstract: The invention relates to compounds of formula (1) and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such derivatives. The compounds according to the present invention are useful in numerous diseases, disorders and conditions, in particular inflammatory, allergic and respiratory diseases, disorders and conditions.
    Type: Grant
    Filed: April 8, 2009
    Date of Patent: August 3, 2010
    Assignee: Pfizer Inc
    Inventors: Alan Daniel Brown, Mark Edward Bunnage, Paul Alan Glossop, Kim James, Charlotte Alice Louise Lane, Russel Andrew Lewthwaite, Ian Brian Moses, David Anthony Price, Nicholas Murray Thomson
  • Patent number: 7754892
    Abstract: Provided are processes for the preparation of N-(2-acetyl-4,6-dimethylphenyl)-3-{[(3,4 dimethyl-5-isoxazolyl)amino]sulfonyl}-2-thiophenecarboxamide, a compound useful for the treatment of endothelin-mediated disorders.
    Type: Grant
    Filed: August 3, 2007
    Date of Patent: July 13, 2010
    Assignee: Encysive Pharmaceuticals, Inc.
    Inventor: John F. Reichwein
  • Patent number: 7745630
    Abstract: Compounds of formula (I), or pharmaceutically acceptable derivatives thereof, wherein: Z, O, A, V, Y and Y? are as defined herein; are useful for treating dysmenorreah.
    Type: Grant
    Filed: December 10, 2004
    Date of Patent: June 29, 2010
    Inventors: Justin Stephen Bryans, Patrick Stephen Johnson, Lee Richard Roberts, Thomas Ryckmans
  • Patent number: 7709444
    Abstract: Pharmaceutical formulations are described comprising an echinocandin compound or echinocandin/carbohydrate complex and a pharmaceutically acceptable micelle-forming surfactant in a non-toxic aqueous solvent such that the solubilization of the echinocandin compound is optimized and the ability to freeze-dry the solution is maintained. Both the solution and freeze-dried formulations have increased stability. A bulking agent, tonicity agent buffer and/or a stabilizing agent may optionally be added to the formulations to further enhance the stability of the formulation.
    Type: Grant
    Filed: April 11, 2005
    Date of Patent: May 4, 2010
    Assignee: Pfizer Inc.
    Inventors: Nathaniel Milton, Kenneth Philip Moder, James Lawrence Sabatowski, Stephanie Ann Sweetana
  • Patent number: 7709473
    Abstract: The invention relates to compounds of formula (I) prodrugs thereof, and the pharmaceutically acceptable salts of the compounds and prodrugs, wherein Ra, Rb, R1 and R2 are as defined herein; pharmaceutical compositions thereof; and uses thereof.
    Type: Grant
    Filed: September 27, 2004
    Date of Patent: May 4, 2010
    Assignee: Pfizer Inc.
    Inventor: John William Benbow
  • Patent number: 7700658
    Abstract: The invention relates to substituted aryl and heteroaryl (R)-Chiral Halogenated 1-Substitutedamino-(n+1)-Alkanol compounds useful as inhibitors of cholesteryl ester transfer protein (CETP; plasma lipid transfer protein-I) and compounds, compositions and methods for treating atherosclerosis and other coronary artery diseases. Novel high yield, stereoselective processes for the preparation of the chiral substituted alkanol compounds from chiral and achiral intermediates are described.
    Type: Grant
    Filed: January 29, 2008
    Date of Patent: April 20, 2010
    Assignee: Pfizer Inc.
    Inventors: James A. Sikorsky, Richard C. Durley, Margaret L. Grapperhaus, Mark A. Massa, Emily J. Reinhard, Yvette M. Fobian, Michael B. Tollefson, Lijuan Wang, Brian S. Hickory, Monica B. Norton, William F. Vernier, Deborah A. Mischke, Michele A. Promo, Ashton T. Hamme, Dale P. Spangler, Melvin L. Rueppel
  • Patent number: 7700618
    Abstract: This invention relates to compounds of the formula (I): or a pharmaceutically acceptable salt thereof, wherein A, R1, R2, R3, R4, R5, m and n are each as described herein, and compositions containing such compounds, and the use of such compounds in the treatment of a condition mediated by CB2 receptor activity such as, but not limited to, inflammatory pain, nociceptive pain, neuropathic pain, fibromyalgia, chronic low back pain, visceral pain, acute cerebral ischemia, pain, chronic pain, acute pain, post herpetic neuralgia, neuropathies, neuralgia, diabetic neuropathy, HIV-related neuropathy, nerve injury, rheumatoid arthritic pain, osteoarthritic pain, back pain, cancer pain, dental pain, fibromyalgia, neuritis, sciatica, inflammation, neurodegenerative disease, cough, broncho constriction, irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), colitis, cerebrovascular ischemia, emesis such as cancer chemotherapy-induced emesis, rheumatoid arthritis, asthma, Crohn's disease, ulcerative colitis, as
    Type: Grant
    Filed: February 23, 2007
    Date of Patent: April 20, 2010
    Assignee: Pfizer Inc
    Inventors: Tomoki Kato, Kana Kon-I, Yohei Yuki, Kazuo Ando
  • Patent number: 7695736
    Abstract: A pharmaceutical composition comprises, in powder form, (a) at least one water-soluble therapeutic agent selected from selective COX-2 inhibitory drugs and prodrugs and salts thereof, for example parecoxib sodium, in a therapeutically effective total amount constituting about 30% to about 90% by weight, (b) a parenterally acceptable buffering agent in an amount of about 5% to about 60% by weight, and optionally (c) other parenterally acceptable excipient ingredients in a total amount not greater than about 10% by weight, of the composition. The composition is reconstitutable in a parenterally acceptable solvent liquid to form an injectable solution. A lyophilization process is provided for preparation of such a composition.
    Type: Grant
    Filed: April 1, 2002
    Date of Patent: April 13, 2010
    Assignee: Pfizer Inc.
    Inventors: Tugrul T. Kararli, Sandeep Nema, Aziz Karim